诱骗受体3与肿瘤的研究进展  

Research progress of decoy receptor 3 in cancer

作　　者：岳庆峰[1] 汪永和(综述)[1] 魏祥志(审校) 

机构地区：[1]合肥市第三人民医院胸外科,230022

出　　处：《肿瘤研究与临床》2012年第5期354-357,共4页Cancer Research and Clinic

基　　金：基金项目：合肥市第三人民医院院内基金（YJ2011-09）

摘　　要：诱骗受体3（DcR3）基因在一些肿瘤细胞中表达明显增加，DcR3通过竞争性阻断与Fas／FasL、LIGHT及TL1A／DR3信号通路，调节细胞增殖、抑制细胞凋亡、逃避免疫监视、形成肿瘤血管，与肿瘤的发生、发展密切相关。DcR3有可能成为一种全新的肿瘤特异性标志物，在肿瘤发生、发展、预防、诊断、治疗、预后及疗效观察方面提供一种新的思路，为临床应用揭开新的篇章。Decoy receptor 3（DcR3） gene expresses highly in some malignant tumors,it involves cellular proliferation regulation, inhibition of apoptosis, immune escape and tumor angiogenesis by competitively blocking the Fas/FasL, LIGHT and TL1A/DR3 signal pathway , therefore it deeply relates to the malignant tumors＇s generation and progression.DcR3 is supposed to be the new tumor-specific marker that may cast the light to the tumor generation, development, prevention, diagnosis, treatment, prognosis and effect observation. DcR3 is expected to be open a new chapter in clinical application.

关 键 词：肿瘤坏死因子诱骗受体 肿瘤 细胞凋亡 研究 

分 类 号：R730.2[医药卫生—肿瘤]